Becoming a father seems to make a man less likely to die young. What’s more, when a father passes away within the first five years of his child’s life, the cause is usually non-natural and thus preventable.
Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.
Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.
Published in Clinical Imaging, the responses indicate that Trump administration policies have made it more difficult to acquire funding and collaborate with other researchers.
Might mammography enhanced by contrast media prove a surer, faster way than other modalities—including digital breast tomosynthesis—to get to a definitive diagnosis for women with dense breast tissue? The American College of Radiology wants to know.
Reviewing data from more than 23.5 million U.S. patients, the study's authors found that methamphetamine use was linked to a whopping 86% increase in a patient's AFib risk. The other substances included in the analysis were not far behind.
The adult brain may be more malleable than scientists previously thought, according to new research presented at the 35th European College of Neuropsychopharmacology.
Children are at heightened risk of major clinical depression when at least one parent has a history of the disorder. New research shows depression markers appearing on structural and functional brain MRI ahead of symptoms in these “familial risk” offspring from infancy through early adulthood.
A team of specialists from Cleveland Clinic reviewed nearly 3,000 medications, writing that a common type 2 diabetes medication offered the most potential as an effective treatment for AFib.
Nearly 30% of corresponding authors included in the analysis shared that they had witnessed scientific fraud in their department within the last five years.
